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Persistence rate (%) was deﬁned as the number of days between
ﬁrst biologic prescription and last biologic encounter, divided by
365 and multiplied by 100. Two mutually exclusive cohorts
were deﬁned based on their persistence rates: patients with per-
sistence >=80% and patients with persistence <80%. Total
health care and medical costs were assessed during the study
period. Per patient per month (PPPM) costs were calculated.
Cost of adverse events could not be identiﬁed separately in this
analysis. A multivariate model was used to adjust for covariates
including age, gender, Charlson Co-morbidity Index (CCI), and
pre-index period health care costs. RESULTS: In all, 358
patients were included, 206 (57.5%) with a persistence rate
<80% and 152 (42.5%) with a persistence rate >=80%. Nearly
half were female and the mean age was 45.2 years. The higher
persistence cohort had lower PPPM medical costs ($359.54
versus $407.14) and total health care costs ($1541.56 versus
$2653.30) compared with the lower persistence cohort. Also,
the multivariate analysis indicated that after adjusting for the
confounding factors: age, gender, CCI, and pre-index period
health care costs, a higher persistence rate is signiﬁcantly asso-
ciated with lower total health care PPPM costs (P < 0.0001).
CONCLUSION: A higher persistence rate with anti-TNF
therapy is associated with lower health care costs. Future studies
to examine the impact of persistence with anti-TNF therapy
on clinical and humanistic outcomes in patients with PsA are
recommended.
ARTHRITIS—Health Care Use & Policy Studies
PAR26
THE UNINTENDED CONSEQUENCES OF WITHDRAWING
DRUGS FROMTHE MARKET
Gilmore A
Health Benchmarks, Inc,Woodland Hills, CA, USA
OBJECTIVES: On September 30, 2004, rofecoxib—a drug used
to treat inﬂammation—was voluntarily withdrawn from the US
market due to mounting evidence of increased cardiovascular
(CV) risk. This study sought to assess movement in the number
of clinically appropriate (CAP) cyclo-oxygenase (COX)-2
prescriptions dispensed after the rofecoxib withdrawal; and
whether patients with CAP proﬁles demonstrated different post-
withdrawal switching behavior or incurred different levels of
health care costs. METHODS: Administrative claims data from
four regional health plans were used. To examine differences in
clinically appropriate prescribing pre- and post-rofecoxib with-
drawal, a generalized estimating equations approach was used.
RESULTS: Based on a total of 317,762 prescriptions, this study
found that CAP prescribing rates were lower after news of the
increased drug risk, as were the total number of COX-2 prescrip-
tions that were clinically inappropriate. Patients with CAP risk
were more likely to exhibit switching behavior by ﬁlling prescrip-
tions for nonselective (ns) NSAIDs or discontinuing use of all
NSAIDs. Health care costs incurred in the year following the
rofecoxib withdrawal were lower for patients who were pre-
scribed COX-2s appropriately. CONCLUSION: These ﬁndings
suggest that the widespread coverage of the rofecoxib with-
drawal, which led to heightened awareness of the drug’s risk
affected consumer demand for COX-2s and may have had unin-
tended consequences in reducing the number of patients who
“should have been” receiving these medications according to
clinical risk. Because patients and physicians were forced to make
a medical decision under risk, increased information of the
beneﬁt-risk tradeoff may have been helpful and may have con-
tributed to greater consumer welfare.
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OBJECTIVES: Pharmacovigilance is a very important tool for
registration authorities and pharmaceutical industries to gather
extra information on effectiveness and adverse effects of widely
used drugs. Therefore, post-marketing research can lead to new
insights on therapeutic usability and consequently changes
in registration ﬁles or even result in market withdrawal. In
September 2004, rofecoxib was withdrawn from the market for
reasons of serious cardiovascular adverse events. Our objective
was to evaluate trends in market-share and expenditures of
cyclooxygenase-2 (cox-2) selective and non-selective NSAIDs
around market withdrawal of rofecoxib. METHODS: Analyses
were conducted using pharmacy prescription data from IADB.nl
(50 pharmacies), covering a Dutch population of 500,000 sub-
jects. NSAID-use was calculated per 10,000 of the population
and presented quarterly from 2000–2006. Expenditures related
to NSAID-use were calculated and presented in costs per 1000 of
the population. RESULTS: After market introduction of cox-2
selective NSAIDs, proportional use increased to a maximum of
17% in the third quarter of 2004. After market withdrawal of
rofecoxib, the number of subjects receiving celecoxib and etori-
coxib increased enormously (from 22 to 48 and 18 to 28 subjects
per 10,000 population, respectively), but decreased shortly there-
after. Similar results were found for new users. After market
withdrawal, costs per 1000 population decreased with 65% and
24% for cox-2 selective and the total group of NSAIDs, respec-
tively. During additional study follow-up, costs per DDD were
generally increasing for cox-2 selective and decreasing for other
NSAIDs. Further results will be presented on switching patterns
from rofecoxib to other NSAIDs, with a speciﬁc focus on con-
comitant use of proton-pump-inhibitors for gastrointestinal pro-
tection and related extra costs. CONCLUSION: Withdrawal of
rofecoxib from the Dutch market resulted in a decreasing
number of subjects receiving cox-2 selective NSAIDs (class-
effect) and lower expenditures for the whole group of NSAIDs.
Further research is currently conducted to complete the full eco-
nomic picture.
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OBJECTIVES: The pharmacological prescription can present
geographical variation due to multiple factors. The aim of this
communication is to introduce the spatial variability in the evalu-
ation of different individual outcomes. METHODS: Pharmaco-
logical prescription data of 10,410 persons with diagnosis of
osteoarthrosis were analyzed. The prescriptions were fulﬁlled
during the year 2006 in the health department 11 of the Comu-
nitat Valenciana (Spain). The number of recipes, the number of
prescribed principles and the pharmaceutical expense for every
patient were evaluated. The relationship with gender and age was
explored by means of generalized linear models. The geographi-
cal variation between different administrative units is introduced
by means of heterogeneity and structured random effects. The
proposed hierarchical models were analyzed using Bayesian
methods with MCMC procedures. RESULTS: Models with
random spatial effects explain an important part of the variabil-
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ity and ﬁt better. As a measure of quality of the ﬁtted model
we have chosen the Deviance Information Criteria (DIC). The
improvement in the deviance of the model for the number of
principles per patient is of 1790 and in DIC of 1760. The maps
reveal geographical inequalities and zones with greater average
values. CONCLUSION: The Bayesian hierarchical models have
been a very useful tool for incorporating geographical informa-
tion in the analysis of pharmacological prescription data. They
allow mapping spatial components expressing the trend of that
geographical variation.
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OBJECTIVES: Pharmacogenetics holds the promise of pre-
venting adverse drug events (ADRs) but the diffusion of these
diagnostic testsis still limited. Assessing cost-effectiveness of
pharmacogenetic interventions, a key to successful clinical imple-
mentation, requires access to data on ADRs and related costs
which are not readily available. This study focuses on ADRs
induced by azathioprine (AZA) treatment in Rheumatoid Arthri-
tis and Inﬂammatory Bowel Disease patients, for whom there is
a recognized association between the occurrence of severe neu-
tropenia and the diminished activity of TPMT. The study aims at
evaluating the availability and quality of cost data related to: (i)
the treatment and management of ADRs induced by AZA and (ii)
the use of TPMT diagnostic kits in an average laboratory. The
overall objective is to review the possibility of building a cost-
effectiveness model on European data. METHODS: A literature
review was conducted on PubMED and Embase databases.. The
clinical path for the management of AZA-induced ADRs was
elaborated with an international panel of gastroenterologists/
rheumatologists. RESULTS: Very few studies describe costs of
treating ADRs induced by AZA. When present, costs are rarely
collected empirically but derived from national tariff databases
or from a single health care organization, resulting in a large
variability. Reported costs are only direct, disregarding produc-
tivity losses, while ADRs often require hospitalization. Direct
annual costs for ADRs range from €476 to €5505. It is equally
difﬁcult to identify solid data on the costs o TPMT diagnostic
tests in an average European laboratory, with estimates between
70€ and 130€. CONCLUSION: Cost-effectiveness data might
inﬂuence the degree of conﬁdence of health care organizations in
adopting new technologies. Published economic studies that
evaluate TPMT diagnostic tests and the costs they might prevent
are still rather weak. Prospective economic studies, that system-
atically include the evaluation of ADR costs, are urgently needed.
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OBJECTIVES: To evaluate switching patterns among anti-tumor
necrosis factor therapies (anti-TNFs) in rheumatoid arthritis
(RA) patients. METHODS: A retrospective patient chart review
study was conducted in six rheumatology clinics across the US.
The ﬁrst anti-TNF encounter among RA patients between 2002
and 2004 was identiﬁed. Patients were required to have a
minimum of 12 months of continuous records prior to and
following their index biologic date. Three mutually exclusive
cohorts were developed based on biologic therapy: inﬂiximab,
etanercept or adalimumab. Switching was deﬁned as discontinu-
ation of the index anti-TNF and initiation of another anti-TNF
agent. The rates of switching and time before switching were
examined. RESULTS: Of 496 patients analyzed, 266 (53.6%)
received inﬂiximab, 146 (29.4%) received etanercept, and 84
(14.1%) received adalimumab. 74% of patients were female,
with an average age of 56.1 years. Overall, 87 (17.5%) patients
switched anti-TNF therapy during the follow-up period.
Patients in the inﬂiximab group had a lower switch rate (31
patients, 11.7%) compared with patients in the etanercept (38
patients, 26%) and adalimumab (18 patients, 21.4%) groups.
Chi-Square analyses indicated the differences among three
groups were statistically signiﬁcant (p < 0.001). The inﬂiximab
group had a longer average time before switching (342 days),
compared with those in the etanercept (266 days) and adali-
mumab (341 days) groups; (p = ns). Lack of effectiveness and
safety concerns were the most common reasons for switching
(28.6%). CONCLUSION: The switching rate and time before
switching are important measures of the effectiveness of RA
treatment in real world practice. This chart review study found
that inﬂiximab is associated with a lower switching rate and
longer time before switching, as compared with etanercept
and adalimumab, both of which had higher switching rates and
shorter time to switching. Further studies to evaluate the asso-
ciation of switching with clinical, economic, and humanistic
outcomes are recommended.
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MULTILEVEL ANALYSIS:A NOVEL APPROACH FOR
STATISTICAL ANALYSIS OF LONGITUDINAL STUDIES
IN ORTHOPAEDICS
Aulakh TS, Robinson EV, Kuiper JH, Richardson JB
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OBJECTIVES: Analysis of functional data from longitudinal
studies is usually complicated by missing data. The use of
repeated measures ANOVA for statistical analysis tends to
decrease the sample size and thus affect power and signiﬁcance
of the results. The present study aims to address this problem
with use of hierarchical regression or multilevel modeling.
METHODS: We analysed functional results of 4777 patients
following hip resurfacing arthroplasty. These patients were fol-
lowed annually using Harris Hip score and Merle d’Aubigné
score. Individual domains of Pain, mobility and range of move-
ment were recorded. The scores comprised a follow up period of
nine years with some missing values. The data was analysed
using multilevel techniques in statistical package SYSTAT 11.0.
Model was ﬁtted at two levels, with level one being the scores
and level two the patients. RESULTS: In all the domains of
function, pain and movement, pre operative score and gender
were signiﬁcantly associated with post operative hip function
(p <= 0.05). A better pre op score predicted a better post op score
and male gender was associated with better overall function.
There was a consistent inverse relationship of overall functional
improvement with individual domains of pain and movement.
This implied that a good pre-operative pain score will have less
improvement over time as compared to a poor pre-operative pain
score. There was no signiﬁcant effect of age on the overall func-
tional results (p = 0.492). CONCLUSION: Functional outcome
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